|
|||||
|
|
Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies |
|
| Authors: | Yaojie Zhou Chengdi Wang Yuting Jiang Pengwei Ren Jun Shao Paierhati Tuersun |
| Affiliation: | 1. Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China;2. West China Medical School, Sichuan University, Chengdu, China;3. Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, China |
| Abstract: | Abstract BackgroundAnti-PD-1/PD-L1-based therapy has emerged recently, and we aimed to figure out the latent value of different clinical and molecular factors to predict the efficacy of immune checkpoint inhibitors (ICIs) therapy compared with non-immunotherapy in the first-line setting. |
| Keywords: | Immune checkpoint inhibitors biomarker PD-1 inhibitor PD-L1 inhibitor cancer |